SightfileU.S. market data from official filings

Companies › CLDX

CELLDEX THERAPEUTICS INC NEW (CLDX)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0000744218 · EDGAR filings · Updated 2026-07-15

CELLDEX THERAPEUTICS INC NEW (CLDX) has reported institutional ownership of 92.5%, with 230 institutional managers holding positions valued at $2.31B per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Institutional ownership
92.5%
Institutional managers
230
Reported 13F value
$2.31B
Insider activity
10 trans.
−$1.32M net selling
Data flags
1 active
from SEC filings

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, CELLDEX THERAPEUTICS INC NEW has 230 institutional holders and institutional ownership of 92.5%.

Insider activity

Insiders reported 10 transactions (0 buys, 4 sells) across 4 reporting insiders, with a net reported value of −$1.32M.

Data flags from SEC filings

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2020-05-06 (recurring since 2020-03-26) — source filing. The authoritative details are those stated in the filing itself.

Related companies

SYNDAX PHARMACEUTICALS INC (SNDX) · LIQUIDIA CORPORATION COM NEW (LQDA) · STOKE THERAPEUTICS INC (STOK) · WARBY PARKER INC CL A COM (WRBY) · SUMMIT THERAPEUTICS INC (SMMT) · GENMAB A/S (GMAB)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-15.